📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Surface Ophthalmics

1.1 - Company Overview

Surface Ophthalmics Logo

Surface Ophthalmics

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of ophthalmic therapeutics leveraging the Klarity delivery vehicle, including SURF-100 topical eyedrops for chronic dry eye (Phase II), SURF-200 for acute dry eye (Phase II), SURF-201 Betamethasone 0.2% solution for post-cataract pain and inflammation (positive Phase II), and an MPA 0.1% chronic dry eye therapy ready for Phase III.

Products and services

  • MPA 0.1% & proprietary vehicle: Custom-formulated ophthalmic product for chronic dry eye therapy, incorporating 0.1% MPA in a proprietary vehicle and ready for Phase III clinical trials
  • SURF-201: Steroid-based topical solution containing Betamethasone 0.2% in the Klarity vehicle for reducing post‑cataract surgery pain and inflammation, with positive Phase II clinical results
  • SURF-100: Clinical-stage topical eyedrop for chronic dry eye disease utilizing the Klarity delivery vehicle, currently in Phase II clinical trials

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Surface Ophthalmics

Celerion Logo

Celerion

HQ: United States Website
  • Description: Provider of early clinical research and Applied Translational Medicine, translating research discoveries into knowledge of drug action in humans to support early development decisions. Services include bioanalytical sciences for small and large molecules; clinical development (safety, PK/PD); data management and biometrics; global drug development (regulatory, project management); EDC; and eTMF via secure, DIA-formatted portal.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Celerion company profile →
Genetic Logo

Genetic

HQ: Italy Website
  • Description: Provider of integrated pharmaceutical research, development, manufacturing and licensing of pharmaceutical specialties and medical devices, focused on respiratory and ophthalmology. Offers proprietary medicines (nebulization and oral liquids, tablets, capsules), ophthalmic and respiratory products (pMDI, nebulizers), preservative-free eye drops and nasal sprays, out-licensing/third-party production, and pharmacovigilance.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Genetic company profile →
BCI Pharma Logo

BCI Pharma

HQ: France Website
  • Description: Provider of kinase inhibitor discovery and development solutions, including a proprietary platform to identify novel, potent and selective kinase inhibitors for various diseases; medicinal chemistry and biology laboratories for design, synthesis and cell-based assay development; a preclinical candidate for peripheral neuropathic pain and psoriasis; and risk-sharing collaborations on kinase research projects.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full BCI Pharma company profile →
Bioscript Logo

Bioscript

HQ: United Kingdom Website
  • Description: Provider of regulatory consulting, product lifecycle support, and strategic medical communications services. Offerings include medical communications, market access consulting, regulatory writing, Bioscript Data Insights with tools like KOLNavigator, PubsNavigator and EventsNavigator, plus rare disease and oncology consulting covering strategy, engagement, communications, market access and regulatory writing.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Bioscript company profile →
Ventus Therapeutics Logo

Ventus Therapeutics

HQ: United States Website
  • Description: Provider of novel small molecule medicines targeting the innate immune system to treat autoimmune and inflammatory diseases and cancer. Offers VENT-03, a first-in-class oral cGAS inhibitor in Phase 1; VENT-02, a brain-penetrant NLRP3 inhibitor in Phase 1 for neuro-inflammation and neurodegeneration; and ReSOLVE, a structural biology and computational chemistry platform for small molecule drug discovery.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Ventus Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Surface Ophthalmics

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Surface Ophthalmics

2.2 - Growth funds investing in similar companies to Surface Ophthalmics

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Surface Ophthalmics

4.2 - Public trading comparable groups for Surface Ophthalmics

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Surface Ophthalmics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Surface Ophthalmics

What does Surface Ophthalmics do?

Surface Ophthalmics is a provider of ophthalmic therapeutics leveraging the Klarity delivery vehicle, including SURF-100 topical eyedrops for chronic dry eye (Phase II), SURF-200 for acute dry eye (Phase II), SURF-201 Betamethasone 0.2% solution for post-cataract pain and inflammation (positive Phase II), and an MPA 0.1% chronic dry eye therapy ready for Phase III.

Who are Surface Ophthalmics's competitors?

Surface Ophthalmics's competitors and similar companies include Celerion, Genetic, BCI Pharma, Bioscript, and Ventus Therapeutics.

Where is Surface Ophthalmics headquartered?

Surface Ophthalmics is headquartered in United States.

How many employees does Surface Ophthalmics have?

Surface Ophthalmics has 1,000 employees 🔒.

When was Surface Ophthalmics founded?

Surface Ophthalmics was founded in 2010 🔒.

What sector and industry vertical is Surface Ophthalmics in?

Surface Ophthalmics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Surface Ophthalmics

Who are the top strategic acquirers in Surface Ophthalmics's sector and industry

Top strategic M&A buyers and acquirers in Surface Ophthalmics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Surface Ophthalmics?

Top strategic M&A buyers groups and sectors for Surface Ophthalmics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Surface Ophthalmics's sector and industry vertical

Which are the top PE firms investing in Surface Ophthalmics's sector and industry vertical?

Top PE firms investing in Surface Ophthalmics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Surface Ophthalmics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Surface Ophthalmics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Surface Ophthalmics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Surface Ophthalmics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Surface Ophthalmics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Surface Ophthalmics?

The key public trading comparables and valuation benchmarks for Surface Ophthalmics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Surface Ophthalmics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Surface Ophthalmics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Surface Ophthalmics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Surface Ophthalmics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Surface Ophthalmics's' sector and industry vertical?

Access recent funding rounds and capital raises in Surface Ophthalmics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Surface Ophthalmics